Home Newsfeeds CORRECTION: Lipocine Q4 EPS $(0.03), Inline

CORRECTION: Lipocine Q4 EPS $(0.03), Inline

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 121.43 percent decrease over earnings of $0.14 per share from the same period last year.

byHappy Mohamed

March 10, 2023

1 minute read

J&J’s Tentative $700M Agreement To Resolve Talc Powder-Related Lawsuits Across US States

By Vandana Singh

January 8, 12:19 PM

Healthcare giant Johnson & Johnson (NYSE: JNJ) has reached a tentative agreement to pay approximately $700 million to settle an investigation

JNJ

Nvidia Stock Remains A Bargain Despite More Than Tripling In 2023, Says Bernstein Analyst: ‘Cheapest AI Play’

By Rounak Jain

December 16, 1:02 AM

Bernstein Research senior semiconductor analyst Stacy Rasgon thinks the Nvidia stock is still a value purchase, with a target price of $700.

AMD

Expedia Reports Q4 Results, Joins Pinterest, Affirm Holdings And Other Big Stocks Moving Lower In Friday’s Pre-Market Session

By Avi Kapoor

February 9, 5:57 AM

U.S. stock futures were mixed this morning, with the Dow futures trading lower by around 15 points on Friday.

ABNB

ICON Announces Pricing Of $2B Notes

By Benzinga Newsdesk

April 30, 5:45 PM

ICON plc (NASDAQ:ICLR) ("ICON"), a world-leading healthcare intelligence and clinical research organization, today announced the pricing of a USD 2 billion SEC-registered bond offering, consisting of $750,000,000 5.809%

ICLR

CORRECTION: Lipocine Q4 EPS $(0.03), Inline

Related Posts

J&J’s Tentative $700M Agreement To Resolve Talc Powder-Related Lawsuits Across US States

Nvidia Stock Remains A Bargain Despite More Than Tripling In 2023, Says Bernstein Analyst: ‘Cheapest AI Play’

Expedia Reports Q4 Results, Joins Pinterest, Affirm Holdings And Other Big Stocks Moving Lower In Friday’s Pre-Market Session

ICON Announces Pricing Of $2B Notes